Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone-Reference-Cited by-同舟云学术

Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

Published:2012-10 Issue:1 Volume:127 Page:161-167
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Krasner Carolyn N.,Poveda Andres,Herzog Thomas J.,Vermorken Jan B.,Kaye Stanley B.,Nieto Antonio,Claret Pilar Lardelli,Park Youn Choi,Parekh Trilok,Monk Bradley J.

Funder

Janssen Research and Development

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference29 articles.

1. Ovarian cancer;Hennessy;Lancet,2009

2. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment;Del Campo;Gynecol Oncol,1994

3. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N Engl J Med,2006

4. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.;Aabo;Br J Cancer,1998

5. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation;Health Technology Assessment;2024-08

2. Systematic Review of the Literature on Multiple Co-occurring Symptoms in Patients Receiving Treatment for Gynecologic Cancers;Seminars in Oncology Nursing;2024-02

3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

4. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer;Cancer Medicine;2023-05-15

5. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities;Cancers;2023-01-10